Published Scientific Research

The International Hyperhidrosis Society was founded in 2003 by a group of dedicated physicians and medical professionals with a commitment to scientific rigor in hyperhidrosis and related fields. As part of that commitment, we keep an extensive inventory of published scientific literature relevant to hyperhidrosis and share it with you, here. We believe it's vital to review published clinical data whenever discussing or reporting on health and hyperhidrosis and we strongly encourage product and treatment development teams to conduct rigorous testing and to espouse only that which can be validated.

Below you will find chronological links to articles, posters, and study data representing the most current peer-reviewed medical and scientific information available on the physiology, treatment, and effects of hyperhidrosis. New data will be posted as it becomes available. Use this rich library of research to inform your decisions and perceptions.

Are you working on research in hyperhidrosis? We can help in many ways!

Want to provide a grant to support hyperhidrosis research? Just send an email to our Executive Director, Lisa J. Pieretti via our Contact Us form.

And, as always, your donations are vital to our continued, collective work toward better care, improved lives, and greater understanding.

We do our best to scour all publications and post hyperhidrosis research here, but if we have missed something, please let us know. We will be happy to include it!

2018 studies

Glaser DA, Hebert A, Pieretti L, Pariser D. Understanding Patient Experience with Hyperhidrosis: A National Survey of 1,985 Patients. Journal fo Drugs in Dermatology. 2018 17(4):392-396

2017 studies

Kamudoni P, Mueller B, Halford J, Schouveller A, Stacey B, Salek MS. The impact of hyperhidrosis on patients' daily life and quality of life: a qualitative investigation. Health and Quality of Life Outcomes. 2017 15:121.

Grabell D, Hebert A. Current and Emerging Medical Therapies for Primary Hyperhidrosis. Dermatol Ther (Heidelb). 2017 Mar; 7(1): 25–36.

Hebert A, Glaser DA, Ballard A, Pieretti L, Trindade de Almeida A, Pariser D. Prevalence of primary focal hyperhidrosis among teens 12-17 in US Population. Abstract (5192) presented at American Academy of Dermatology March 2017, Late-Breaking Research: Clinical Studies/Pediatric (F072).

Pariser D, Krishnaraja J, Tremblay T, Rubison M, Love T, McGraw B. Randomized, Placebo- and Active-Controlled Crossover Study of the Safety and Efficacy THVD-102, a Fixed-dose Combination of Oxybutynin and Pilocarpine, in Subjects with Primary Focal Hyperhidrosis. Journal of Drugs in Dermatology 2017 Feb 1;16(2): 127-132. 

Dagash H, McCaffery S, Mellor K, Roycroft A, Helbling I. Tap water iontophoresis in the treatment of pediatric hyperhidrosis. J Pediatr Surg. 2017 Feb;52(2):309-312. 

Hsu TH, Chen YT, Tu YK, Li CN. A systematic review of microwave-based therapy for axillary hyperhidrosis. J Cosmet Laser Ther. 2017 Mar 10. doi: 10.1080/14764172.2017.1303168.

Millan-Cayetano JF, et al.  Initial study of transdermal oxybutynin for treating hyperhidrosis.  J Dermatol doi:  10.1111/1346-8138.13748.  Published online January 20, 2017.  

2016 studies

Overwhelming foot odor. J Fam Pract. 2016 January;65(1)

Owen K. Excessive Sweating: Are Patients Suffering Unnecessarily? The Journal for Nurse Practitioners, January 2016, Volume 12, Issue 1, 35–40

Cruddas L, Baker DM. Treatment of primary hyperhidrosis with oral anticholinergic medications: a systematic review. J Eur Acad Dermatol Venereol. 2016 Dec 15. doi: 10.1111/jdv.14081.

Hansen CR, Godfrey B. Residual Limb Hyperhidrosis Managed by Botulinum Toxin Injections, Enhanced by the Iodine-Starch Test: A Case Report. American Academy of Physical Medicine and Rehabilitation. 2016 Oct 22. pii: S1934-1482(16)31056-5.

Muthusamy A, Gajendran R, Ponnan S, Thangavel D, Rangan V. A Study on the Impact of Hyperhidrosis on the Quality of Life among College Students. Journal of Clinical and Diagnostic Research: JCDR. 2016;10(6):CC08-CC10.

Ismail D, Madhwapathi V, Ladoyanni E. Focal Hyperhidrosis Associated with Recurrent Urinary Tract Infections. Case Reports in Dermatological Medicine. 2016;2016:3842984.

del Boz J et al. Individualized Dosing of Oral Oxybutynin for the Treatment of Primary Focal Hyperhidrosis in Children and Teenagers. Pediatr Dermatol (2016) 33: 327–331.

Glaser D, Ballard A, Hunt N, Pieretti L & Pariser D. Prevalence of multifocal primary hyperhidrosis and symptom severity over time: results of a targeted survey. Dermatol Surg 42:12 (2016): 1347-1353.

Shayesteh A, Janlert U, Brulin C, Boman J, Nylander E. Prevalence and characteristics of hyperhidrosis in Sweden:  a cross-sectional study inthe general population.  Dermatology doi:  10.1159/000448032.

Doolittle J, Walker P, Mills T, et al. Hyperhidrosis:  an update on prevalence and severity in the United States.  Arch Dermatol Res doi:  10.1007/s00403-016-1697-9.  Published online October 15, 2016.

Bahar R, Zhou P, Liu Y, Huang Y, Phillips A, Lee T, et al. The prevalence of anxiety and depression in patients with or without hyperhidrosis (HH). J Am Acad Dermatol 75:6 (2016):  1126-1133. 

Cramer DW, Vitonis AF, Terry KL, Welch WR, et al. The association between talc use and ovarian cancer: a retrospective case-control study in two US states. Epidemiology. 2016 May;27(3):334-46. 

Liu Y, Bahar R, Kalia S, Huang RY, Phillips A, Su M, et al.  Hyperhidrosis prevalence and demographical characteristics in dermatology outpatients in Shanghai and Vancouver.  PLoS One doi: 10.1371/journal.pone.0153719.  Published online April 22, 2016.

Risacher SL, McDonald BC, Tallman EF, et al. Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal adults. JAMA Neurol. doi:10.1001/jamaneurol.2016.0508. Published online April 18, 2016. 

Singh S, Kaur S, Wilson P. Early experience with endoscopic lumbar sympathectomy for plantar hyperhidrosis. Asian J Endosc Surg. 2016 May;9(2):128-34

2015 studies

Lima SO et al. Research of primary hyperhidrosis in students of medicine of the State of Sergipe, Brazil. Anais Brasileiros de Dermatologia. 2015;90(5):661-665.

Hansen C et al. Incidence, severity, and impact of hyperhidrosis in people with lower-limb amputation. J Rehabil Res Dev. 2015;52(1):31–40.

Ma C, Sivamani RK. Acupuncture as a Treatment Modality in Dermatology: A Systematic Review. J Altern Complement Med. 2015 Sep;21(9):520-9.

Gray, Shelly L PharmD, MS, et al. Cumulative use of strong anticholingerics and incident of dementia. JAMA Intern Med doi: 10.1001/jamainternmed.2014.7663. Published online January 26, 2015. 

Campbell NL, Boustani MA. Adverse cognitive effects of medications. Turning attention to reversibility. Invited commentary. JAMA Intern Med doi: 10.1001/jamainternmed.2014.7667. 

Nicholas R, Quddas A, Baker DM. Treatment of Primary Craniofacial Hyperhidrosis: A Systemic Review. Am J Clin Dermatol. 2015 Oct;16(5):361-70. doi: 10.1007/s40257-015-0136-6.

Schollhammer M, Brenaut E, Menard-Andivot N, Pillette-Delarue M, et al. (2015). Oxybutynin as a treatment for generalized hyperhidrosis: a randomized, placebo-controlled trial. British Journal of Dermatology, 173: 1163-1168. doi: 10.1111/bjd.13973

2014 studies

Bohaty, Benjamin R. MD & Hebert, Adelaide A. MD. Special considerations for children with hyperhidrosis. Dermatologic Clinics 32:4 (2014): 477-484. 

Caplin D, Austin J. Clinical evaluation and quantitative analysis of axillary hyperhidrosis treated with a unique targeted laser energy delivery method with 1-year follow up. J Drugs Dermatol 13:4 (2014): 449-456. 

Hamm, Henning MD. Impact of hyperhidrosis on quality of life and its assessment. Dermatologic Clinics 32:4 (2014): 467-476.

Laniosz, V, et al. Dermatologic manifestations of fibromyalgia. Clin Rheumatol doi: 10.1007/s10067-014-2488-3. Published online January 14, 2014. 

Klar, Joakim, et al.  Abolished InsP3R2 function inhibits sweat secretion in both humans and mice. J Clin Invest doi:  10.1172/JCI70720.  Published online October 20, 2014. 

Moraites, Eleni MD, et al. Incidence and prevalence of hyperhidrosis. Dermatologic Clinics 32:4 (2014): 457-465.

Nestor MS, Park H. Safety and efficacy of micro-focused ultrasound plus visualization for the treatment of axillary hyperhidrosis. J ClinAesthet Dermatol 7:4 (2014):  14-21.

Pariser D,  Ballard A. Topical therapies in hyperhidrosis care. Dermatologic Clinics 32:4 (2014): 485-490.

Pariser D, Ballard A. Iontophoresis for palmar and plantar hyperhidrosis. Dermatologic Clinics 32:4 (2014): 491-494. 

Trindade de Almeida A,  Montagner S. Botulinum toxin for axillary hyperhidrosis. Dermatologic Clinics 32:4 (2014): 495-504. 

Weinberg T et al. Botulinum neurotoxin treatment of palmar and plantar hyperhidrosis. Dermatologic Clinics 32:4 (2014): 505-515.

Glaser DA, Galperin TA. Botulinum toxin for hyperhidrosis of areas other than the axillae and palms/soles. Dermatologic Clinics 32:4 (2014): 517-525.

Glaser DA. Oral medications. Dermatologic Clinics 32:4 (2014): 527-532.

Glaser DA, Galperin TA. Local procedural approaches for axillary hyperhidrosis. Dermatologic Clinics 32:4 (2014): 533-540. 

Moraites E et al. Endoscopic thoracic sympathectomy. Dermatologic Clinics 32:4 (2014): 541-548.

Glaser, DA, Galperin T. Managing hyperhidrosis: emerging therapies. Dermatologic Clinics 32:4 (2014): 549-553.

Pieretti L. Resources for hyperhidrosis sufferers, patients, and health care providers. Dermatologic Clinics 32:4 (2014): 555-564. 

Pariser DM. Incorporating diagnosis and treatment of hyperhidrosis into clinical practice. Dermatologic Clinics 32:4 (2014): 565-574. 

Mela S, Whitworth DE. The fist bump: a more hygienic alternative to the handshake.  American Journal of Infection Control 42:8 (2014):  916-917.

Sklansky M et al. Banning the handshake from the health care setting. JAMA 311:24 (2014):  2477-2478. 

Boschert S.  Laser therapy improved severe hyperhidrosis. Dermatology News, 30 April 2014.  

Pinson I  et al. Non-invasive short-wave guided radiofrequency device for long-term sweat reduction in patients with primary axillary hyperhidrosis:  a preliminary study, presented at the 34 ASLMS Annual Conference, April 4-6, 2014, Phoenix, AZ.

Laniosz V, Wetter DA, Godar DA. Dermatologic manifestations of fibromyalgia. Clin Rheumatol 2014 Jul;33(7):1009-13.

2013 studies

Augustin M, Radtke MA, Herberger K, Kornek T, Heigel H & Schaefer I. Prevalence and disease burden of hyperhidrosis in the adult population. Dermatology 227 (2013):  10-13.  

Terry KL, Karageorgi S, Shvetsov YB, Merritt MA, et al. Genital powder use and risk of ovarian cancer: A pooled analysis of 8,525 cases and 9,859 controls. Cancer Prev Res (Phila). 2013 Aug;6(80): 811-21.

de Menezes LR. Visual scale for the quantification of hyperhidrosis. J. bras. Pneumol 39:4 (2013). 

Fatemi A. Apparatus for the treatment of hyperhidrosis. Patent EP 2645954 A1.  9 October 2013.

Fujimoto T, Kawahara K, Yokozeki H. Epidemiological study and considerations of primary focal hyperhidrosis in Japan:  fromquestionnaire analysis. J Dermatol 40:11 (2013):  886-890. 

Patakfalvi L, Benohanian A. Treatment of palmar hyperhidrosis with needle-free injection of botulinum toxin A.  Arch Dermatol Res doi:  10.1007/s00403-013-1425-7

Gordon JRS, Hill SE. Update on pediatric hyperhidrosis. Dermatologic Therapy 26 (2013): 452-461.

Lee S et al. The efficacy of a microwave device for treating axillary hyperhidrosis and osmidrosis in Asians: a preliminary study. J Cosmet Laser Ther 15:5 (2013):  255-259. 

Jacob C. Treatment of hyperhidrosis with microwave technology. Seminars in Cutaneous Medicine and Surgery 32 (2013):  2-8.

Rokhsar C, Kim MJ. A retrospective analysis of the treatment of axillary hyperhidrosis with a novel microwave technology, presented at the 33rd ASLMS Annual Conference, April 3-7, 2013, Boston, MA.

Biehle-Hulette S et al. Significant protection from event sweat – without a prescription, presented at the American Academy of Dermatology 71st Annual Meeting, March 1-5, 2013, Miami Beach, FL . 

Scarff JR. Options for treating antidepressant-induced sweating. Current Psychiatry 12:1 (2013): 51.

2012 studies

Letada, PR, et al. Treatment of focal axillary hyperhidrosis using a long-pulsed Nd:YAG 1064 nm laser at hair reduction settings. J Drugs Dermatol 11:1 (2012): 59-63. 

Gagnon L. Laser therapy provides permanent solution to hyperhidrosis. Dermatology Times, 1 July 2012.  

Bechara FG, et al. Effects of a long-pulsed 800-nm diode laser on axillary hyperhidrosis: a randomized controlled half-side comparison study. Dermatol Surg 38:5 (2012): 736-740. 

Glaser DA et al. A randomized, blinded clinical evaluation of a novel microwave device for treating axillary hyperhidrosis: the dermatologic reduction in underarm perspiration study. Dermatol Surg 38 (2012): 185-191. 

JohnsonJ et al.  Microwave thermolysis of sweat glands.  Lasers in Surgery and Medicine 44:1 (2012):  20-25.  

Wolosker N et al. "A randomized placebo-controlled trial of oxybutynin for the initial treatment of palmar and axillary hyperhidrosis". Journal of Vascular Surgery 55:6 (2012): 1696-1700.

Paller AS et al. Oral glycopyrrolate as second-line treatment for primary pediatric hyperhidrosis. J Am Acad Dermatol 67:5 (2012): 918-923. 

Rubin D et al. “Second-hand stress: inhalation of stress sweat enhances neural response to neutral faces”. Soc Cogn Affect Neurosci 7:2 (2012): 208-212.

Kerscher M et al. "Comparison of the spread of three botulinum toxin type A preparations". Arch Dermatol Res 304 (2012): 155-161. 

Kayser SC et al. Perioral gustatory sweating: case report. The Journal of Laryngology & Otology 126 (2012): 532-534.

Hong H et al. Clinical evaluation of a microwave device for treating axillary hyperhidrosis. Dermatol Surg doi: 10.1111/j.1524-4725.2012.02375.x. 

Walling H. Systemic therapy for primary hyperhidrosis: a retrospective study of 59 patients treated with glycopyrrolate or clonidine. J Am Acad Dermatol 66:3 (2012): 387-392.

Wolosker N et al. Evaluation of quality of life over time among 453 patients with hyperhidrosis submitted to endoscopic thoracic sympathectomy. Journal of Vascular Surgery 55:1 (2012): 154-156.

Salvaggio HL, Wagner A. Suture boots: an aid for the injection of onabotulinum toxin A for primary focal hyperhidrosis. Pediatric Dermatology doi: 10.1111/j.1525-1470.2012.01849.x. 

Swaile DF et al. Clinical studies of sweat rate reduction by an over-the-counter soft-solid antiperspirant and comparison with a prescription antiperspirant product in male panelists. Br J Dermatol 166 Suppl. 1 (2012): 22-26.

2011 studies

Saenz JW, Sams RW, Jamieson B. Treatment of Hyperhidrosis. Am Fam Physician. 2011 Feb 15;83(4):464-466.

Maletic D et al. Laser assisted reduction of axillary hyperhidrosis (LARAH) – evaluation of success up to 24 months after the treatment. J. LAHA 2011:1 (2011): 37-42. 

Kotlus BS. Treatment of refractory axillary hyperhidrosis with a 1320-nm Nd:YAG laser. J Cosmet Laser Ther 13:4 (2011): 193-195. 

Smith SR. Evolution of a new treatment modality for primary focal hyperhidrosis, presented at Cosmetic Boot Camp 2011, June 14-17, 2011, Aspen, CO.

Martin A et al. Effective prevention of stress-induced sweating and axillary malodour formation in teenagers. Int J Cosmet Sci 33:1 (2011): 90-97.

Wang F et al. Comparison of compensatory sweating and quality of life following thoracic sympathetic block for palmar hyperhidrosis: electrocautery hook versus titanium clip. Chinese Medical Journal 124:21 (2011): 3495-3498.

Atkinson J  et al. Endoscopic transthoracic limited sympathotomy for palmar-plantar hyperhidrosis: outcomes and complications during a 10-year period. Mayo Clin Proc 86:8 (2011): 721-729.

Walling HW, Swick, BL. Treatment options for hyperhidrosis. Am J Clin Dermatol 12:5 (2011): 285-295.

Wolosker N et al. The use of oxybutynin for treating axillary hyperhidrosis. Annals of Vascular Surgery 25:8 (2011): 1057-1062.

Woolery-Lloyd H, Valins W. Aluminum chloride hexahydrate in a salicylic acid gel base: a case series of combination therapy with botulinum toxin type A for moderate to severe hyperhidrosis. Cutis 88:1 (2011): 43-45.

Milanez de Campos JR et al. Is age group a predictive factor for satisfaction among patients undergoing sympathectomy to treat hyperhidrosis? J Vasc Bras 10:4 (2011): 284-288.

Wolosker N et al. The use of oxybutynin for treating facial hyperhidrosis. An Bras Dermatol 86:3 (2011): 451-456.

Doft MA, et al. Treatment of axillary hyperhidrosis with botulinum toxin: a single surgeon's experience with 53 consecutive patients. Aesthetic Plast Surg 2011 May 11. 

Lupin M et al. A multi-center evaluation of the miradry system to treat subjects with axillary hyperhidrosis, presented at the 31st ASLMS Annual Conference, April 1-3, 2011, Grapevine, TX.

Kilmer S et al. A randomized, blinded clinical study of a microwave device for treatment of axillary hyperhidrosis, presented at the 31st ASLMS Annual Conference, April 1-3, 2011, Grapevine, TX.

2010 studies

Wait SD. et al. Thoracoscopic sympathectomy for hyperhidrosis:  analysis of 642 procedures with special attention to horner’s syndrome and compensatory hyperhidrosis.  Neurosurgery 67:3 (2010):  652-657.

Kaminer MS et al.  First clinical use of a novel microwave device for treatment of axillary hyperhidrosis, presented at the American Society for Dermatologic Surgery 2010 Annual Meeting, October 21-24, 2010, Chicago, IL. 

Marques AH et al. Evaluation of stress symptoms by applying noninvasive methodologies: measurements of neuroimmune biomarkers in the sweat, heart rate variability and salivary cortisol. Neuroimmunomodulation 17:3 (2010): 205-208.

Dressler D. Comparing Botox® and Xeomin® for axillar hyperhidrosis. J Neural Transm 117 (2010): 317-319.

Cantarella G et al. Treatment of Frey’s syndrome with botulinum toxin B. Otolaryngol Head Neck Surg 143 (2010): 214-218.

Glaser DA et al. A randomized, blinded clinical evaluation of a novel microwave device for treatment of axillary hyperhidrosis, presented at the 2010 ASDS/ASCDAS Joint Annual Meeting, October 21-24, 2010, Chicago, IL.

Hill S. Hyperhidrosis Diagnosis and Management. Pediatric Rounds, a newsletter from the physicians of Children's Specialty Group, (Fall 2010) 12-14.

Shams K, Kavanagh GM. Immediate reduction in sweat secretion with electric current application in primary palmar hyperhidrosis. Archdermatol doi: 10.1001/archdermatol.2010.300. 

Bellet JS. Diagnosis and treatment of primary focal hyperhidrosis in children and adolescents. Semin Cutan Med Surg 29:2 (2010): 121-126.

Prasad A et al. Endoscopic thoracic sympathectomy for primary palmar hyperhidrosis. Surg Endosc 24 (2010): 1952-1957.

Milanez de Campos JR et al. Comparison of pain severity following video-assisted thoracoscopic sympathectomy: electric versus harmonic scalpels. Interactive Cardiovascular and Thoracic Surgery 10 (2010): 919-922.

Wolosker Nelson, et al. Is gender a predictive factor for satisfaction among patients undergoing sympathectomy to treat palmar hyperhidrosis? Clinics 65:6 (2010): 583-586.

Wolosker N et al. Quality of life before surgery is a predictive factor for satisfaction among patients undergoing sympathectomy to treat hyperhidrosis. Journal of Vascular Surgery 51:5 (2010): 1190-1194.

2009 studies

Kenny K. Diagnosis and treatment of hyperhidrosis. Nurse Practitioner: July 2009, Volume 34, Issue 7, p 10–11.

Carriere, I et al. Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population. Arch Intern Med 169:14 (2009): 1317-1324.

Commons, GW, Lim AF. Treatment of axillary hyperhidrosis/bromidrosis using Vaser ultrasound. Aesthetic Plast Surg 33:3 (2009): 312-323

Kim WO et al. Botulinum toxin:  a treatment for compensatory hyperhidrosis in the trunk.  Dermatol Surg 35:5 (2009):  833-838.  

Mujica-Parodi LR et al. Chemosensory cues to conspecific emotional stress activate amygdale in humans. PLoS One doi: 10.1371/journal.pone.0006415. 

Prehn-Kristensen A et al. Induction of empathy by the smell of anxiety. PLoS One doi: 10.1371/journal.pone.0005987. 

Scully C et al. Marathon of eponyms: 6 Frey syndrome (gustatory sweating). Oral Diseases 15 (2009): 608-609.

de Bree R et al. Repeated botulinum toxin type A injections to treat patients with Frey syndrome. Arch Otolaryngol Head Neck Surg 135:3 (2009): 287-290.

Ng S et al. Management of Frey syndrome using botulinum neurotoxin: a case report. JCDA 75:9 (2009): 651-654.

Baron JA, Zloty DM. Bilateral type 1 complex regional pain syndrome after local nerve blocks for palmar hyperhidrosis. Dermatol Surg 35 (2009): 885-887.

Mahendiran S et al. Hyperhidrosis: a review of a medical condition. The Open Dermatology Journal 3 (2009): 195-197.

Flanagan KH, Glaser DA. An open-label trial of the efficacy of 15% aluminum chloride in 2% salicylic acid gel base in the treatment of moderate-to-severe primary axillary hyperhidrosis. Journal of Drugs in Dermatology 8:5 (2009): 477-480.

Jones T et al. Safety and tolerability of topical botulinum toxin type A in healthy adults, presented at the 69th Annual Meeting of the Society for Investigative Dermatology, May 2009, Montreal, Canada.

American Academy of Dermatology Responds to FDA Decision Regarding Botulinum Toxin Products, Schaumburg, IL, April 2009.

Walling HW. Primary hyperhidrosis increases the risk of cutaneous infection: a case-control study of 387 patients. J Am Acad Dermatol doi: 10.1016/j.jaad.2009.02.038. 

Keller SM et al. Diagnosis of palmar hyperhidrosis via questionnaire without physical examination. Clin Auton Res doi: 10.1007/s10286-009-0006-5. 

Goldman A, Wollina U. Subdermal Nd-YAG laser for axillary hyperhidrosis. Dermatol Surg 35:6 (June 2009):1018 

Grunfeld A et al. Botulinum toxin for hyperhidrosis. Am J Clin Dermatol 10:2 (2009): 87-102.

Miller DL et al. Effect of sympathectomy level on the incidence of compensatory hyperhidrosis after sympathectomy for palmar hyperhidrosis. J Thorac Cardiovasc Surg 138 (2009): 581-585.

Cruz J et al. Effects of endoscopic thoracic sympathectomy for primary hyperhidrosis on cardiac autonomic nervous activity. The Journal of Thoracic and Cardiovascular Surgery 137:3 (2009): 664-669.

Chow A, Wilder-Smith EP. Effect of transdermal botulinum toxin on sweat secretion in subjects with idiopathic palmar hyperhidrosis. Br J Dermatol 160:3 (2009): 721-722.

2008 studies

Cetindag IB, Boley TM, Webb KN, Hazelrigg SR. Long-term results and quality-of-life measures in the management of hyperhidrosis. ThoracSurg Clin 18:2 (2008):  217-222. 

Kim WO et al. Topical glycopyrrolate for patients with facial hyperhidrosis. Br J Dermatol 158 (2008): 1094-1097.

Laing TA et al. Botulinum toxin for treatment of glandular hypersecretory disorders. Journal of Plastic, Reconstructive & Aesthetic Surgery 61 (2008): 1024-1028.

Bahmer FA, Sachse MM. Hyperhidrosis area and severity index. Dermatol Surg 34 (2008): 1744-1745.

Gelbard CM et al. Primary pediatric hyperhidrosis: a review of current treatment options. Pediatric Dermatology 25:6 (2008): 591-598.

Kossintseva I, Barankin B. Improvement in both raynaud disease and hyperhidrosis in response to botulinum toxin type A treatment. Journal of Cutaneous Medicine and Surgery 12:4 (2008): 189-193.

Efthymiou CA, Thorpe JAC. Compensatory hyperhidrosis: a consequence of truncal sympathectomy treated by video assisted application of botulinum toxin and reoperation. European Journal of Cardio-thoracic Surgery 33 (2008): 1157-1158.

Hartl DM, et al. Botulinum toxin A for quality of life improvement in post-parotidectomy gustatory sweating (Frey’s syndrome). The Journal of Laryngology & Otology 122 (2008): 1100-1104.

Honeyman JF et al. Efficacy of botulinum toxin for a congenital eccrine naevus. J Eur Acad Dermatol Venereol 22:10 (2008): 1275-1276.

Munia MAS et al. Sustained benefit lasting one year from T4 instead of T3-T4 sympathectomy for isolated axillary hyperhidrosis. Clinics 63:6 (2008): 771-774.

Flanagan KH et al. Botulinum toxin type A versus topical 20% aluminum chloride for the treatment of moderate to severe primary focal axillary hyperhidrosis. Journal of Drugs in Dermatology 7:3 (2008): 221-227.

Smalls LK et al. Clinical comparison of otc products labeled prescription strength wetness protection to prescription antiperspirants, presented at the 66th Annual Meeting of the American Academy of Dermatology, February 1-5, 2008, San Antonio, TX.

Smalls LK et. al. Chromophore mapping of hemoglobin for the assessment of axillary irritation: comparison of otc and prescription antiperspirants, presented at the 66th Annual Meeting of the American Academy of Dermatology, February 1-5, 2008, San Antonio, TX.

Cheshire WP, Fealey RD. Drug-induced hyperhidrosis and hypohidrosis. Drug Safety 31:2 (2008): 109-126.

2007 studies

Pomprasit M, Chintrakam C. Treatment of Frey’s syndrome with botulinum toxin. J Med Assoc Thai 90:11 (2007): 2397-2402.

de Bree R et al. Management of Frey syndrome. Head & Neck 29:8 (2007): 773-778.

Na GY et al. Control of palmar hyperhidrosis with a new 'dry-type' iontophoretic device. Dermatol Surg 33 (2007): 57-61.

Solish N et al. A comprehensive approach to the recognition, diagnosis, and severity-based treatment of focal hyperhidrosis: recommendations of the canadian hyperhidrosis advisory committee. Dermatol Surg 33 (2007): 908-923.

Bechara FG et al. Focal hyperhidrosis of the anal fold: successful treatment with botulinum toxin A. Dermatol Surg 33 (2007): 924-927.

NAD Examines Advertising for P&G's Secret Clinical Strength, NAD News, National Advertising Review Council, New York, NY, July 2007.

Glaser DA et al. Primary focal hyperhidrosis: scope of the problem. Cutis 79:suppl 5 (2007): 5-17.

Glaser DA et al. Palmar and plantar hyperhidrosis: best practice recommendations and special considerations. Cutis 79:suppl 5 (2007): 18-28.

Glaser DA et al. Facial hyperhidrosis: best practice recommendations and special considerations. Cutis 79:suppl 5 (2007): 29-32.

Ram R et al. Current and emerging therapeutic modalities for hyperhidrosis, part 2: moderately invasive and invasive procedures. Cosmetic Dermatology 79 (2007): 281-288.

Glaser DA et al. Functional and dermatology-specific quality of life benefits with repeated botulinum toxin type A treatment of primary axillary hyperhidrosis over 4 years, presented at the 65th Annual Meeting of the American Academy of Dermatology, February 2-6, 2007, Washington, DC.

Kessler E et al. A demographical study of hyperhidrosis, presented at the 65th Annual Meeting of the American Academy of Dermatology, February 2-6, 2007, Washington, DC.

Glaser DA et al. 4-Year longitudinal data on the efficacy and safety of repeated botulinum toxin type A therapy for primary axillary hyperhidrosis, presented at the 65th Annual Meeting of the American Academy of Dermatology, February 2-6, 2007, Washington, DC.

Thomas M et al. Alternative topical treatment to an aluminum chloride antiperspirant that provides prescription strength efficacy with significantly less irritation, presented at the 65th Annual Meeting of the American Academy of Dermatology, February 2-6, 2007, Washington, DC.

Munia MAS et al. A randomized trial of T3-T4 versus T4 sympathectomy for isolated axillary hyperhidrosis. Journal of Vascular Surgery 45:1 (2007): 130-133.

Aghaei S. Botulinum toxin therapy for palmar hyperhidrosis: experience in an Iranian population. The International Society of Dermatology 46 (2007): 212-214.

Lear W et al. An epidemiological study of hyperhidrosis. Dermatol Surg 33 (2007): S69-S75.

Talarico-Filho S et al. A double-blind, randomized, comparative study of two type A botulinum toxins in the treatment of primary axillary hyperhidrosis. Dermatol Surg 33 (2007): S44-S50.

Glogau RG. Topically applied botulinum toxin type A for the treatment of primary axillary hyperhidrosis: results of a randomized, blinded, vehicle-controlled study. Dermatol Surg 33 (2007): S76-S80.

2006 studies

Izadi S et al. Mydriasis and accommodative failure from exposure to topical glycopyrrolate used in hyperhidrosis.  J Neuroophthalmol 26 (2006):  232-233.  

Glaser DA. The use of botulinum toxins to treat hyperhidrosis and gustatory sweating syndrome. Neurotoxicity Research 9:2-3 (2006): 173-178.

Dressler D, Eleopra R. Clinical use of non-A botulinum toxins: botulinum toxin type B. Neurotoxicity Research 9:2-3 (2006): 121-125.

Khoo SG et al. The use of botulinum toxin in Frey’s syndrome. IMJ 99:5 (2006): 136-137.

Bakke M et al. Treatment of gustatory sweating with low-dose botulinum toxin A. Acta Odontologica Scandinavica 64:3 (2006): 129-133.

Lim ECH et al. Topical botulinum toxin to treat hyperhidrosis? No sweat! Medical Hypotheses 67 (2006): 27-32.

Milanez de Campos JR et al. Axillary hyperhidrosis: T3/T4 versus T4 thoracic sympathectomy in a series of 276 cases. Journal of Laparoendoscopic & Advanced Surgical Techniques 16:6 (2006): 598-603. 

Barankin B et al. Treatment of inguinal hyperhidrosis with botulinum toxin type A. International Journal of Dermatology 45 (2006): 985-986.

Kavanagh GM, Shams K. Botulinum toxin type A by iontophoresis for primary palmar hyperhidrosis. Journal of the American Academy of Dermatology 55:5 (2006): S115-S117.

Kavanagh GM et al. Topical glycopyrrolate should not be overlooked in treatment of focal hyperhidrosis. British Journal of Dermatology 155:2 (2006): 487.

Pariser D et al. Effect of botulinum toxin type A treatment for severe primary axillary hyperhidrosis on work performance and productivity: results from an open-label clinical study, presented at the 64th Annual Meeting of the American Academy of Dermatology, March 3-7, 2006, San Francisco, CA.

Thomas M et al. Panel discussions among hyperhidrosis patients to assess lifestyle limitations, treatment regimes, and compensating behaviors, presented at the 64th Annual Meeting of the American Academy of Dermatology, March 3-7, 2006, San Francisco, CA.

Hamm H et al. Primary focal hyperhidrosis: disease characteristics and functional impairment. Dermatology 2006 212 (2006): 343-353.

Moya J et al. Thoracic sympathicolysis for primary hyperhidrosis. Surg Endosc 20 (2006): 598-602.

2005 studies

Weber A et al. Psychosocial aspects of patients with focal hyperhidrosis. Marked reduction of social phobia, anxiety and depression and increased quality of life after treatment with botulinum toxin A. British Journal of Dermatology, (2005) 152: 342–345.

Ogata A, et al. Low and high frequency acupuncture stimulation inhibits mental stress-induced sweating in humans via different mechanisms. Auton Neurosci 118: 1-2 (2005): 93-101.

Glaser DA et al. Efficacy and safety of repeated botulinum toxin type A treatment for primary axillary hyperhidrosis: 12-month interim analysis of a multicenter, open-label trial, presented at ACADEMY ’05 American Academy of Dermatology Summer Meeting, July 20-24, 2005, Chicago, IL.

Kowalski JW et al. Cost-effectiveness and budget impact of botulinum toxin type A (BoNTA) treatment for severe primary axillary hyperhidrosis inadequately managed with topical agents, presented at ACADEMY ’05 American Academy of Dermatology Summer Meeting, July 20-24, 2005, Chicago, IL.

Neumayer C et al. Effect of endoscopic thoracic sympathetic block on plantar hyperhidrosis. Arch Surg 140: 676-680 (2005).

Eisenach JH et al. Hyperhidrosis: evolving therapies for a well-established phenomenon. Mayo Clinic Proceedings 80:5 (2005): 657-666.

Solish N et al. Prospective open-label study of botulinum toxin type A in patients with axillary hyperhidrosis: effects on functional impairment and quality of life. Dermatol Surg 31:4 (2005): 405-413.

Cliff SH, Reeken S. Axillary hyperhidrosis and botox responding to demands: starting a nurse-led service. Nurse2Nurse 5:1 (2005): 28-30.

Krogstad AL et al. No compensatory sweating after botulinum toxin treatment of palmar hyperhidrosis. Br J Dermatol 152:2 (Feb 2005): 329-333. 

Haider A, Solish N.Focal hyperhidrosis: diagnosis and management. CMAJ 172:1 (2005): 1-7.

2004 studies

Thomas S, Brown J, Vafaie J, Schwartz R. Palmoplantar Hyperhidrosis: A Therapeutic Challenge. Am Fam Physician. 2004 Mar 1;69(5):1117-1121.

Dickerson SS, Kemeny ME. Acute stressors and cortisol responses: a theoretical integration and synthesis of laboratory research. Psychol Bull 130:3 (2004): 355-391.

Lowe N et al. The place of botulinum toxin type A in the treatment of focal hyperhidrosis. Br J Dermatol 151:6 (Dec 2004): 1115-1122. 

Lee J et al. A case of foul genital odor treated with botulinum toxin A. Dermatologic Surgery doi: 10.1111/j.1524-4725.2004.30382.x. 

Campanati A et al. Local neural block at the wrist for treatment of palmar hyperhidrosis with botulinum toxin: technical improvements. Journal of the American Academy of Dermatology 51:3 (2004): 345-348.

Strutton D et al. US prevalence of hyperhidrosis and impact on individuals with axillary hyperhidrosis: results from a national survey. Journal of the American Academy of Dermatology 51:2 (2004): 241-248.

Hornberger J et al. Recognition, diagnosis, and treatment of primary focal hyperhidrosis. Journal of the American Academy of Dermatology 51:2 (2004): 274-286.

Glaser DA et al. Botulinum toxin type A improves occupational impairment associated with primary axillary hyperhidrosis and results in high levels of satisfaction with treatment, presented at the American Academy of Dermatology Summer Meeting, July 28- August 1, 2004, New York, NY.

Carruthers A, Carruthers J. Long-term safety review of subjects treated with botulinum toxin type A for cosmetic use, presented at the American Academy of Dermatology Summer Meeting, July 28- August 1, 2004, New York, NY.

Dolianitis C et al. Iontophoresis with glycopyrrolate for the treatment of palmoplantar hyperhidrosis. Australasian Journal of Dermatology 45 (2004): 208-212.

Kavanagh GM et al. Botox® delivery by iontophoresis. British Journal of Dermatology 151 (2004): 1093-1095.

Kowalski JW, Eadie N, Dagget S, Lai PY. Validity and reliability of the hyperhidrosis disease severity scale (HDSS). J Am Acad Dermatol 50:3 (2004):  P51.

Ojimba TA, Cameron AEP. Drawbacks of endoscopic thoracic sympathectomy. British Journal of Surgery 91 (2004): 264-269.

Hund M et al. Randomised, placebo-controlled, double blind clinical trial for the evaluation of the efficacy and safety of oral methanthelinium bromide (Vagantin®) in the treatment of focal hyperhidrosis. JDDG;2004· 2:343-349. (English, without graphs)

Hund M et al. Randomised, placebo-controlled, double blind clinical trial for the evaluation of the efficacy and safety of oral methanthelinium bromide (Vagantin®) in the treatment of focal hyperhidrosis. JDDG;2004· 2:343-349. (German, with graphs)

Hexsel DM et al. Inguinal, or hexsel’s hyperhidrosis. Clinics in Dermatology 22 (2004): 53-59.

2003 studies

Atkinson JLD, Fealey RD. Sympathotomy instead of sympathectomy for palmar hyperhidrosis: minimizing postoperative compensatory hyperhidrosis. Mayo Clinic Proceedings 78:2 (2003): 167-172.

Gossot D et al. Long-term results of endoscopic thoracic sympathectomy for upper limb hyperhidrosis. Ann Thoracic Surg 75 (2003): 1075-1079.

Naumann M et al. Botulinum toxin type A is a safe and effective treatment for axillary hyperhidrosis over 16 months. Arch Dermatol 139 (2003): 731-736.

Connolly M, de Berker D. Management of primary hyperhidrosis. Am J Clin Dermatol 4:10 (2003): 681-697.

Kaufmann H et al. Primary hyperhidrosis. Clin Auton Res 13 (2003): 96-98.

2002 studies

Ro KM, Cantor RM, Lange KL, Ahn SS. Palmar hyperhidrosis:  evidence of genetic transmission. J Vasc Surg 35:2 (2002):  382-386. 

Karakoç Y, et al. Safe control of palmoplantar hyperhidrosis with direct electrical current. Int J Dermatol 41 (2002): 602-605.

Tögel B et al. Current therapeutic strategies for hyperhidrosis: a review. Eur J Dermatol 12 (2002):  219-223. 

Atkins JL, Butler PE. Hyperhidrosis:  a review of current management. Plast Reconstr Surg 110 (2002):  222-228.  

Ackerl K et al. The scent of fear. Neuro Endocrinol Lett 23:2 (2002): 79-84.

Tan SR, Solish N. Long-term efficacy and quality of life in the treatment of focal hyperhidrosis with botulinum toxin A. Dermatol Surg 28:6 (2002): 495-499.

Davidson JRT et al. Hyperhidrosis in social anxiety disorder. Progress in Neuro-Psychopharmacology & Biological Psychiatry 26 (2002): 1327-1331.

Naumann MK et al. Effect of botulinum toxin type A on quality of life measures in patients with excessive axillary sweating: a randomized controlled trial. Brit J Dermatol 147 (2002): 1218-1226.

2001 studies

Naumann M, Lowe NJ. Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomized, parallel group, double blind, placebo controlled trial. BMJ 323 (2001): 596-599.

2000 studies

Collin J, Whatling P. Treating hyperhidrosis: surgery and botulinum toxin are treatments of choice in severe cases. BMJ 320 (2000):  1221-1222.

Kinkelin I et al. Effective treatment of frontal hyperhidrosis with botulinum toxin A. British Journal of Dermatology143:4 (2000): 824-827.

Swinehart JM. Treatment of axillary hyperhidrosis: combination of the starch-iodine test with the tumescent liposuction technique. Dermatol Surg 26 (2000): 392-396

1999 studies

Cina CS, Clase CM. The illness intrusiveness rating scale: a measure of severity in individuals with hyperhidrosis. Qual Life Res 8 (1999):693-698.  

Leung AK, Chan PY, Choi MC. Hyperhidrosis. Int J Dermatol 38:8 (1999):  561-567. 

1998 studies

Glogau RG.  Botulinum A neurotoxin for axillary hyperhidrosis.  No sweat Botox. Dermatol Surg 24 (1998):  817-819. 

Benohanian A et al. Localized hyperhidrosis treated with aluminum chloride in a salicylic acid gel base. International Journal of Dermatology 37 (1998): 701-703.

Stolman LP. MD. Treatment of hyperhidrosis. Dermatologic Clinics 16:4 (October 1998): 863-867.

1997 studies

Park JH et al. Carbon dioxide laser treatment vs subcutaneous resection of axillary osmidrosis. Dermatol Surg 23:4 (1997): 247-251. 

1993 studies

Kirschbaum C et al. The ‘Trier Social Stress Test’ – a tool for investigating psychobiological stress responses in a laboratory setting. Neuropsychobiology 28: 1-2 (1993): 76-81.

1992 studies

Harlow BL, Cramer DW, Bell DA, Welch WR. Perineal exposure to talc and ovarian cancer risk. Obstet Gynecol. 1992 Jul;80(1):19-26. 

1989 studies

Dahl JC, Glent-Madsen L. Treatment of hyperhidrosis manuum by tap water iontophoresis. Acta Derm Venereol 69 (1989): 346-348.  

1988 studies

Glent-Madsen L, Dahl JC. Axillary hyperhidrosis: local treatment with aluminum-chloride hexahydrate 25% in absolute ethanol with and without supplementary treatment with triethanolamine. Acta Derm Venereol 68 (1988): 87-89. 

1987 studies

Stolman LP. Treatment of excess sweating of the palms by iontophoresis. Arch Dermatol 123 (July 1987): 893-896.

1986 studies

White JW. Treatment of primary hyperhidrosis. Mayo Clin Proc 61 (1986):  951-956. 

1984 studies

Hölzle E, Braun-Falco O. Structural changes in axillary eccrine glands following long-term treatment with aluminum chloride hexahydrate solution. Br J Dermatol 110 (1984):  399-403.

1982 studies

Cramer DW, Welch WR, Scully RE, Wojciechowski CA. Ovarian cancer and talc. A case-controlled study. Cancer 50 (1982): 372-376.

1981 studies

Hill, AC, et al. Mechanism of action of iontophoresis in the treatment of palmar hyperhidrosis. Cutis 28 (1981): 69-70,72.  

1980 studies

Levit F. Treatment of hyperhidrosis by tap water iontophoresis. Cutis 26 (August 1980): 192-194.

1978 studies

Hays LL. The Frey syndrome: a review and double blind evaluation of the topical use of a new anticholinergic agent. Laryngoscope 88 (1978): 1796-1824.  

1977 studies

Adar R et al. Palmar hyperhidrosis and its surgical treatment: a report of 100 cases. Ann Surg 186 (1977):  34-41. 

1951 studies

Bouman HD, Lentzer EM. The treatment of hyperhidrosis of hands and feet with constant current. Am J Phys Med 31 (1952): 158-169. 

Pin It

International Hyperhidrosis Society

Support the International Hyperhidrosis Society by sponsoring a page!

Click here

Sign Up for Our News Blog

Page 1 of 4

  1. Get inside intel, research results, event invites!
  2. First Name*
    Please type your first name.
  3. Last Name
    Please type your last name.
  4. Email*
    Invalid email address.
  5. Year of Birth*
    Invalid Input
  1. Gender*
    Please indicate your gender.
  2. Tell us about you.*

    Please tell us who you are in the hyperhidrosis community.
  1. Country*
    Please select your country where you live.
  2. Postal or Zip Code*
    Invalid Input
  1. Where do you sweat excessively?*

    Please tell us where you sweat so we can help you and others.
  2. Fight SPAM
    Invalid Input

Non-profit shout-outs

 logo exchange silver 128x94

International Hyperhidrosis Society has received the GuideStar Exchange Seal a leading symbol of transparency and accountability provided by GuideStar, the premier source of nonprofit information.




International Hyperhidrosis Society has been awarded as a Top-Rated NonProfit for five years in a row! Read the reviews and add your own.

  • Topics in this issue of Dermatologic Clinics include: Incidence and prevalence; Impact on quality of life; Special considerations of hyperhidrosis in children; Topical therapies; Iontophoresis; Botox for axillary hyperhidrosis; Botox for palmar/plantar hyperhidrosis; Botox for other hyperhidrosis; Systemic therapies for hyperhidrosis; Procedural approaches; Endoscopic thoracic sympathectomy; Emerging and investigative treatments; Resources for patients and physicians; Incorporating diagnosis and treatment into clinical practice. Dr David Pariser is Editor of this publication; a founding member of the International Hyperhidrosis Society and renown researcher and lecturer on mechanism, diagnosis, and treatment of hyperhidrosis, Dr Pariser continues to investigate therapies that are effective for patients.


    A Catwork Orange